Improved treatment results in childhood acute myelogenous leukemia: an update of the German cooperative study AML-BFM-78.

Improved results in treatment of acute myelogenous leukemia in children--report of the German cooperative AML study BFM-78.

Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78.

One hundred fifty-one children with acute myelogenous leukemia (AML) entered the cooperative study BFM-78 between December 1978 and October 1982. The initial therapy consisted of an intensive induction and consolidation regimen over eight weeks with seven different drugs and cranial irradiation. It was followed by maintenance with thioguanine and cytosine arabinoside for two years and additiona...

Treatment results in childhood AML, with special reference to the German studies BFM-78 and BFM-83.

The number of children with acute myelogenous leukemia (AML) who achieve remission and the number of long-term survivors have increased in the last 10 years owing to intensified chemotherapy and better supportive care. This report reviews nine pediatric studies, particularly the German AML studies BFM-78 and BFM-83. A total of 294 children with AML under 17 years of age entered the AML studies ...

Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group.

The main difference between the two cooperative studies on therapy of childhood acute myelogenous leukemia AML-BFM-78 and AML-BFM-83 was the addition of an 8-day ADE (cytosine arabinoside, daunorubicin, etoposide) induction treatment in the second study. Due to this intensification, the relapse rate, but not the rate of induction failures, was reduced. The probability of a 6-year event-free sur...

Familial Acute Myelogenous Leukemia: Report of Three Cases

Acute myelogenous leukemia (AML) is a hematological malignancy, which accounts for about 15-25% of childhood's leukemia. Genetic factor is one of the most important predisposing elements in childhood acute leukemia, especially AML. In this case report, a rare presentation of familial AML is presented in three monozygotic triplets. Two were 10 months old, and the other one was 16 months old at p...